Company: WHWK
Filing Date: 2025-01-31
Form Type: DEFM14A
Source: 0001193125-25-018470
Chunk: 449

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-01-31
Form: DEFM14A
Chunk 449
---
 public, legislatures, regulators and the investment 
 community;                                                                                               |

| • |     | general market conditions and other factors unrelated to our operating performance or the operating performance                                                                                
 of our competitors, including turmoil in the global banking system, deteriorating market conditions due to investor concerns regarding inflation and conflicts in Ukraine and the Middle East; |

| • |     | adverse publicity relating to our markets, including with respect to other products and potential products in 
 such markets;                                                                                                 |

| • |     | the introduction of technological innovations or new therapies competing with our products and potential 
 products;                                                                                                |

| • |     | announcements of significant acquisitions, strategic collaborations, joint ventures or capital commitments by us 
 or our competitors;                                                                                              |

- 303 -

| • |     | disputes or other developments relating to proprietary rights, including patents, litigation matters, and our 
 ability to obtain patent protection for our technologies;                                                     |

| • |     | the hiring or loss of key employees; |

| • |     | significant lawsuits, including patent or stockholder litigation; |

| • |     | if securities or industry analysts do not publish research or reports about our business, or if they issue an 
 adverse or misleading opinion regarding our business and stock;                                               |

| • |     | changes in the market valuations of similar companies; |

| • |     | general and industry-specific economic conditions potentially affecting our research and development 
 expenditures;                                                                                        |

| • |     | sales of our common stock by us or our stockholders in the future, or the anticipation thereof; |

| • |     | trading volume of our common stock; |

| • |     | changes in the structure of health care payment systems; |

| • |     | adverse regulatory decisions; |

| • |     | trading volume of our common stock; and |

| • |     | period-to-period fluctuations in 
 our financial results.           |

Moreover, the stock markets in general have experienced substantial volatility that has often been unrelated to the operating performance of individual companies or the biotechnology sector. These broad market fluctuations may also adversely affect the trading price of our common stock. In the past, following periods of volatility in the market price of a company’s securities, stockholders have often instituted class action securities litigation against those companies. Regardless of the merits or the ultimate results of such litigation, if instituted, such litigation could result in substantial costs and diversion of management’s attention and resources, which could significantly harm our profitability and reputation. Additionally, a decrease in our